As of today (2024-05-05), Bioverativ's share price is $104.98. Bioverativ's Tangible Book per Share of Dec. 2017 for the quarter that ended in Dec. 2017 was $0.84. Hence, Bioverativ's Price to Tangible Book Ratio of today is 124.83.
The historical rank and industry rank for Bioverativ's Price-to-Tangible-Book or its related term are showing as below:
BIVV's Price-to-Tangible-Book is not ranked *
in the Biotechnology industry.
Industry Median: 2.715 * Ranked among companies with meaningful Price-to-Tangible-Book only.
The historical data trend for Bioverativ's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Bioverativ's Price-to-Tangible-Book
For the Biotechnology subindustry, Bioverativ's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioverativ's Price-to-Tangible-Book Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bioverativ's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Bioverativ's Price-to-Tangible-Book falls into.
Bioverativ Price-to-Tangible-Book Calculation
Bioverativ's price-to-tangible-book ratio for today is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Bioverativ Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of Bioverativ's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Bioverativ Inc is a biotech focused on rare blood disorders and has two marketed hemophilia products: Eloctate (hemophilia A) and Alprolix (hemophilia B). Bioverativ spun off from Biogen in February 2017. Bioverativ's partner Swedish Orphan Biovitrum holds rights to these therapies and pipeline hemophilia therapies in many markets outside the U.S. Bioverativ is building a pipeline in rare blood-related disorders, such as TNT009 (part of the True North acquisition) in cold agglutinin disease and other hematology-focused drug candidates. Sanofi's pending acquisition of Bioverativ was announced in January 2018.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BIVV has been successfully added to your 